Datametrex AI (TSXV: DM) is expected to see its health division grow as a result of the exploding cases of the coronavirus. The firm this morning issued a brief update, indicating it has been requested to increase its services substantially to the film and production industry.
The company has reportedly been requested to increase weekly testing measures by 300% in the face of rising positive cases in Canada, with a 24 hour rotation to go into effect, effective immediately. The firm was previously on a 72 hour rotation to test production sets.
As a comparison to the prior quarter, the firm in Q3 conducted a total of 67,500 tests for 41 production companies. 28 sets were found in Vancouver, 11 in Toronto, and 2 in Montreal.
As per the company, the increased testing is expected to result in “a significant increase in revenue in the COVID-19 business.”
Datametrex AI last traded at $0.19 on the TSX Venture.
FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.